featured
2023 Top Story in Oncology: Vorasidenib for IDH1- or IDH2-Mutant Low-Grade Glioma
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389(7):589-601.
- Wen PY, Mellinghoff IK, van den Bent MJ, et al. LTBK-06. Impact of Vorasidenib Treatment on Mutant IDH1 or IDH2 Diffuse Glioma Tumor Growth Rate: Results From the Randomized, Double-Blind, Phase 3 Indigo Study. Neuro Oncol. 2023;25(Suppl_5):v310–v311.
- Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1521-1532.
Disclosure statements are available on the authors' profiles:
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.